Oruka Therapeutics: The Psoriasis Market Is Becoming A Barbell, And ORKA-001 Owns The Far End

Impact · against what's priced in

Oruka Therapeutics is positioned as a high-potential play in the psoriasis market due to ORKA-001's potential to combine Skyrizi-level efficacy with lower dosing frequency. While the cash position is strong, the stock's upside depends on upcoming Phase 3 initiation and specific trial data milestones.

ORKA+0.60

No priced-in read yet